Cardio Diagnostics holds investor call; highlights $854 CMS rate, new CLIA lab, and India expansion

Cardio Diagnostics Holdings, Inc.

Investor presentation reveals $854 final CMS gapfill rate for both Epi+Gen CHD and PrecisionCHD tests.
New internal CLIA lab reduces initial COGS by ~30%; further reductions expected at scale.
TAM estimated at ~$176B across both tests, with 146M and 60M eligible Americans respectively.
Announced partnership with Aimil Ltd and Dr. Lal PathLabs for India expansion of PrecisionCHD.
Preliminary data on PrecisionCHD presented at AHA and ACC conferences showing INOCA detection and ACS mortality prediction.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.